{"id":"https://openalex.org/W2162946017","doi":"https://doi.org/10.1001/archgenpsychiatry.2011.132","title":"Trajectories of Depression Severity in Clinical Trials of Duloxetine: Insights Into Antidepressant and Placebo Responses","display_name":"Trajectories of Depression Severity in Clinical Trials of Duloxetine: Insights Into Antidepressant and Placebo Responses","alternate_titles":[],"publication_year":2011,"publication_date":"2011-12-01","ids":{"openalex":"https://openalex.org/W2162946017","doi":"https://doi.org/10.1001/archgenpsychiatry.2011.132","mag":"2162946017","pmid":"https://pubmed.ncbi.nlm.nih.gov/22147842","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3339151"},"language":"en","primary_location":{"id":"doi:10.1001/archgenpsychiatry.2011.132","doi":"https://doi.org/10.1001/archgenpsychiatry.2011.132","is_oa":true,"landing_page_url":"https://doi.org/10.1001/archgenpsychiatry.2011.132","pdf_url":"https://jamanetwork.com/journals/jamapsychiatry/articlepdf/1107437/yoa15069_1227_1237.pdf","source":{"id":"https://openalex.org/S126359496","display_name":"Archives of General Psychiatry","issn_l":"0003-990X","issn":["0003-990X","1538-3636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archives of General Psychiatry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2162946017"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://jamanetwork.com/journals/jamapsychiatry/articlepdf/1107437/yoa15069_1227_1237.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052366236","display_name":"Ralitza V. Gueorguieva","orcid":"https://orcid.org/0000-0003-0944-5973","observed_orcids":["https://orcid.org/0000-0003-0944-5973"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I3019813218","display_name":"Abbott (United Kingdom)","ror":"https://ror.org/03wnay029","country_code":"GB","type":"company","lineage":["https://openalex.org/I3019813218","https://openalex.org/I4210088555"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]},{"id":"https://openalex.org/I4210086971","display_name":"VA Connecticut Healthcare System","ror":"https://ror.org/000rgm762","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210086971","https://openalex.org/I4210095851"]},{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4210107416","display_name":"Roche (France)","ror":"https://ror.org/01mqmer16","country_code":"FR","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210107416"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]},{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]},{"id":"https://openalex.org/I4210158294","display_name":"National Center for Post Traumatic Stress Disorder","ror":"https://ror.org/04xv0vq46","country_code":"US","type":"facility","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695","https://openalex.org/I4210119030","https://openalex.org/I4210158294"]},{"id":"https://openalex.org/I4391012632","display_name":"Forest Laboratories (United States)","ror":"https://ror.org/01p3wva84","country_code":"US","type":"company","lineage":["https://openalex.org/I4391012632"]},{"id":"https://openalex.org/I44892455","display_name":"Takeda (Japan)","ror":"https://ror.org/04hjbmv12","country_code":"JP","type":"company","lineage":["https://openalex.org/I44892455"]},{"id":"https://openalex.org/I883203835","display_name":"Mallinckrodt (Ireland)","ror":"https://ror.org/00467td76","country_code":"IE","type":"company","lineage":["https://openalex.org/I4210102181","https://openalex.org/I883203835"]}],"countries":["FR","GB","IE","JP","US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Ralitza Gueorguieva","raw_affiliation_strings":["Division of Biostatistics, School of Public Health, Yale University School of Medicine, New Haven, CT 06520-8034, USA. ralitza.gueorguieva@yale.edu","Aisling Capital LLC, Astra-Zeneca Pharmaceuticals, Biocortech, Brintnall & Nicolini Inc, Easton Associates, Gilead Sciences Inc, GlaxoSmithKline, Janssen Pharmaceuticals, Lundbeck Research USA, Medivation Inc, Merz Pharmaceuticals, MK Medical Communications, Pfizer Pharmaceuticals, F. Hoffmann-La Roche Ltd, SK Holdings Co Ltd, Sunovion Pharaceuticals Inc, Takeda Industries, Teva Pharmaceutical Industries Ltd, and Transcept Pharmaceuticals. Dr Krystal","Division of Biostatistics, School of Public Health (Dr Gueorguieva), and Department of Psychiatry (Dr Krystal), Yale University School of Medicine, New Haven, and Veterans Affairs National Center for Posttraumatic Stress Disorder,","Division of Biostatistics, School of Public Health, Yale University School of Medicine, 60 College St, Room 215B, New Haven, CT 06520-8034","Dr Mallinckrodt","Eli Lilly and Company, Indianapolis, Indiana (","Veterans Affairs Connecticut Healthcare System, West Haven (Dr Krystal), Connecticut; and Lilly Research Laboratories,","advisory board of Abbott Laboratories, Bristol-Myers Squibb, Eisasi Inc, Eli Lilly and Co, Forest Laboratories, Lohocla Research Corporation, Mnemosyne Pharaceuticals Inc, Naurex Inc, Pfizer Pharmaceuticals, and Shire Pharmaceuticals"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Biostatistics, School of Public Health, Yale University School of Medicine, New Haven, CT 06520-8034, USA. ralitza.gueorguieva@yale.edu","institution_ids":["https://openalex.org/I32971472"]},{"raw_affiliation_string":"Aisling Capital LLC, Astra-Zeneca Pharmaceuticals, Biocortech, Brintnall & Nicolini Inc, Easton Associates, Gilead Sciences Inc, GlaxoSmithKline, Janssen Pharmaceuticals, Lundbeck Research USA, Medivation Inc, Merz Pharmaceuticals, MK Medical Communications, Pfizer Pharmaceuticals, F. Hoffmann-La Roche Ltd, SK Holdings Co Ltd, Sunovion Pharaceuticals Inc, Takeda Industries, Teva Pharmaceutical Industries Ltd, and Transcept Pharmaceuticals. Dr Krystal","institution_ids":["https://openalex.org/I4210107416","https://openalex.org/I4210114143","https://openalex.org/I4210140176","https://openalex.org/I44892455"]},{"raw_affiliation_string":"Division of Biostatistics, School of Public Health (Dr Gueorguieva), and Department of Psychiatry (Dr Krystal), Yale University School of Medicine, New Haven, and Veterans Affairs National Center for Posttraumatic Stress Disorder,","institution_ids":["https://openalex.org/I32971472","https://openalex.org/I4210158294"]},{"raw_affiliation_string":"Division of Biostatistics, School of Public Health, Yale University School of Medicine, 60 College St, Room 215B, New Haven, CT 06520-8034","institution_ids":["https://openalex.org/I32971472"]},{"raw_affiliation_string":"Dr Mallinckrodt","institution_ids":["https://openalex.org/I883203835"]},{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana (","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Veterans Affairs Connecticut Healthcare System, West Haven (Dr Krystal), Connecticut; and Lilly Research Laboratories,","institution_ids":["https://openalex.org/I4210086971"]},{"raw_affiliation_string":"advisory board of Abbott Laboratories, Bristol-Myers Squibb, Eisasi Inc, Eli Lilly and Co, Forest Laboratories, Lohocla Research Corporation, Mnemosyne Pharaceuticals Inc, Naurex Inc, Pfizer Pharmaceuticals, and Shire Pharmaceuticals","institution_ids":["https://openalex.org/I3019813218","https://openalex.org/I4210091812","https://openalex.org/I4391012632"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Craig Mallinckrodt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Craig Mallinckrodt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"John H Krystal","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"John H Krystal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":12,"corresponding_author_ids":["https://openalex.org/A5052366236"],"corresponding_institution_ids":["https://openalex.org/I168537998","https://openalex.org/I3019813218","https://openalex.org/I32971472","https://openalex.org/I4210086971","https://openalex.org/I4210091812","https://openalex.org/I4210107416","https://openalex.org/I4210114143","https://openalex.org/I4210140176","https://openalex.org/I4210158294","https://openalex.org/I4391012632","https://openalex.org/I44892455","https://openalex.org/I883203835"],"apc_list":null,"apc_paid":null,"fwci":7.7796,"has_fulltext":true,"cited_by_count":131,"citation_normalized_percentile":{"value":0.9807093,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"68","issue":"12","first_page":"1227","last_page":"1227"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9824000000953674,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9824000000953674,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":0.0038999998942017555,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12035","display_name":"Pain Management and Placebo Effect","score":0.0024999999441206455,"subfield":{"id":"https://openalex.org/subfields/2805","display_name":"Cognitive Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/duloxetine","display_name":"duloxetine","score":0.8949999809265137},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.9290000200271606},{"id":"https://openalex.org/keywords/placebo-response","display_name":"placebo response","score":0.7710000276565552},{"id":"https://openalex.org/keywords/growth-mixture-modeling","display_name":"growth mixture modeling","score":0.8479999899864197},{"id":"https://openalex.org/keywords/treatment-response-trajectories","display_name":"treatment response trajectories","score":0.6980000138282776},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.9319999814033508},{"id":"https://openalex.org/keywords/serotonergic-antidepressants","display_name":"serotonergic antidepressants","score":0.9739999771118164},{"id":"https://openalex.org/keywords/hamilton-depression-rating-scale","display_name":"Hamilton Depression Rating Scale","score":0.5680000185966492},{"id":"https://openalex.org/keywords/treatment-response-biomarkers","display_name":"treatment response biomarkers","score":0.7239999771118164}],"concepts":[{"id":"https://openalex.org/C2780764818","wikidata":"https://www.wikidata.org/wiki/Q411932","display_name":"Duloxetine","level":3,"score":0.8927021622657776},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7784793376922607},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.5688525438308716},{"id":"https://openalex.org/C2910564767","wikidata":"https://www.wikidata.org/wiki/Q411932","display_name":"Duloxetine Hydrochloride","level":4,"score":0.5556365251541138},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5047959089279175},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.4813297688961029},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.46075281500816345},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.44862866401672363},{"id":"https://openalex.org/C2776867660","wikidata":"https://www.wikidata.org/wiki/Q1814941","display_name":"Depression (economics)","level":2,"score":0.4264797568321228},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.3827277421951294},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3536459505558014},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.34628134965896606},{"id":"https://openalex.org/C2780733359","wikidata":"https://www.wikidata.org/wiki/Q331769","display_name":"Mood","level":2,"score":0.1741510033607483},{"id":"https://openalex.org/C139719470","wikidata":"https://www.wikidata.org/wiki/Q39680","display_name":"Macroeconomics","level":1,"score":0.0},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000068736","descriptor_name":"Duloxetine Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003627","descriptor_name":"Data Interpretation, Statistical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010352","descriptor_name":"Patient Dropouts","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015990","descriptor_name":"Placebo Effect","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D016014","descriptor_name":"Linear Models","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1001/archgenpsychiatry.2011.132","doi":"https://doi.org/10.1001/archgenpsychiatry.2011.132","is_oa":true,"landing_page_url":"https://doi.org/10.1001/archgenpsychiatry.2011.132","pdf_url":"https://jamanetwork.com/journals/jamapsychiatry/articlepdf/1107437/yoa15069_1227_1237.pdf","source":{"id":"https://openalex.org/S126359496","display_name":"Archives of General Psychiatry","issn_l":"0003-990X","issn":["0003-990X","1538-3636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archives of General Psychiatry","raw_type":"journal-article"},{"id":"pmid:22147842","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22147842","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archives of general psychiatry","raw_type":"Journal Article"},{"id":"pmh:oai:europepmc.org:2510392","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3339151","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3339151","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3339151/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Arch Gen Psychiatry","raw_type":"Text"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.310.3197","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.310.3197","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://www.statmodel.com/download/Gueorguieva et al 2011 Archives of Gen Psychiatry.pdf","raw_type":"text"}],"best_oa_location":{"id":"doi:10.1001/archgenpsychiatry.2011.132","doi":"https://doi.org/10.1001/archgenpsychiatry.2011.132","is_oa":true,"landing_page_url":"https://doi.org/10.1001/archgenpsychiatry.2011.132","pdf_url":"https://jamanetwork.com/journals/jamapsychiatry/articlepdf/1107437/yoa15069_1227_1237.pdf","source":{"id":"https://openalex.org/S126359496","display_name":"Archives of General Psychiatry","issn_l":"0003-990X","issn":["0003-990X","1538-3636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archives of General Psychiatry","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[{"id":"https://openalex.org/G8052269359","display_name":"Yale University Clinical and Translational Science Award Program","funder_award_id":"UL1RR024139","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"},{"id":"https://openalex.org/G8560923713","display_name":"AMINO ACID NEUROTRANSMITTER DYSREGULATION IN ALCOHOLISM","funder_award_id":"K05AA014906","funder_id":"https://openalex.org/F4320337330","funder_display_name":"National Institute on Alcohol Abuse and Alcoholism"},{"id":"https://openalex.org/G9000858992","display_name":"Center for the Translational Neuroscience of Alcoholism","funder_award_id":"P50AA012870","funder_id":"https://openalex.org/F4320337330","funder_display_name":"National Institute on Alcohol Abuse and Alcoholism"}],"funders":[{"id":"https://openalex.org/F4320306127","display_name":"U.S. Department of Veterans Affairs","ror":"https://ror.org/05rsv9s98"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320334434","display_name":"National Center for PTSD, U.S. Department of Veterans Affairs","ror":"https://ror.org/04xv0vq46"},{"id":"https://openalex.org/F4320337330","display_name":"National Institute on Alcohol Abuse and Alcoholism","ror":"https://ror.org/02jzrsm59"},{"id":"https://openalex.org/F4320337375","display_name":"National Center for Research Resources","ror":"https://ror.org/04pw6fb54"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2162946017.pdf","grobid_xml":"https://content.openalex.org/works/W2162946017.grobid-xml"},"referenced_works_count":72,"referenced_works":["https://openalex.org/W69501187","https://openalex.org/W141876393","https://openalex.org/W179572412","https://openalex.org/W283310529","https://openalex.org/W1542738148","https://openalex.org/W1794165588","https://openalex.org/W1967799878","https://openalex.org/W1973026623","https://openalex.org/W1974840855","https://openalex.org/W1979796529","https://openalex.org/W1983284282","https://openalex.org/W1994809535","https://openalex.org/W2000769256","https://openalex.org/W2003363634","https://openalex.org/W2011390619","https://openalex.org/W2022569343","https://openalex.org/W2024012851","https://openalex.org/W2041085272","https://openalex.org/W2044579390","https://openalex.org/W2045106443","https://openalex.org/W2047902057","https://openalex.org/W2048211507","https://openalex.org/W2049032077","https://openalex.org/W2049571898","https://openalex.org/W2057964179","https://openalex.org/W2058667310","https://openalex.org/W2060614575","https://openalex.org/W2065145667","https://openalex.org/W2068876013","https://openalex.org/W2069090735","https://openalex.org/W2072221629","https://openalex.org/W2084168719","https://openalex.org/W2085470365","https://openalex.org/W2091407410","https://openalex.org/W2094300830","https://openalex.org/W2098616868","https://openalex.org/W2114559667","https://openalex.org/W2114613490","https://openalex.org/W2116153150","https://openalex.org/W2121016639","https://openalex.org/W2121297553","https://openalex.org/W2121690051","https://openalex.org/W2123160535","https://openalex.org/W2124136543","https://openalex.org/W2124295641","https://openalex.org/W2132699864","https://openalex.org/W2136630776","https://openalex.org/W2140505555","https://openalex.org/W2141773277","https://openalex.org/W2145816995","https://openalex.org/W2146659162","https://openalex.org/W2150921722","https://openalex.org/W2153403353","https://openalex.org/W2153592073","https://openalex.org/W2157069028","https://openalex.org/W2164666909","https://openalex.org/W2164816593","https://openalex.org/W2166423384","https://openalex.org/W2167761850","https://openalex.org/W2167802580","https://openalex.org/W2168355170","https://openalex.org/W2168622268","https://openalex.org/W2317157238","https://openalex.org/W2332421802","https://openalex.org/W2408828150","https://openalex.org/W2797458901","https://openalex.org/W2984684056","https://openalex.org/W3099028081","https://openalex.org/W3114568810","https://openalex.org/W4252663544","https://openalex.org/W6602780416","https://openalex.org/W6815276817"],"related_works":["https://openalex.org/W2279076250","https://openalex.org/W1982960635","https://openalex.org/W2141773277","https://openalex.org/W3091567232","https://openalex.org/W2586756570","https://openalex.org/W2972543417","https://openalex.org/W3176998317","https://openalex.org/W4415773175","https://openalex.org/W4289786561"],"abstract_inverted_index":{"CONTEXT:":[0],"The":[1],"high":[2,14],"percentage":[3],"of":[4,21,49,59,65,95,108,130,140,172,175,181,211,260,281,284,304],"failed":[5],"clinical":[6,47,57,128,251],"trials":[7,48,58,129],"in":[8,28,46,78,85,90,116,165,200,307],"depression":[9],"may":[10],"be":[11],"due":[12],"to":[13,25,61,258],"placebo":[15,44,92,133,205],"response":[16,192],"rates":[17],"and":[18,43,82,89,103,134,148,164,178,195,202,287],"the":[19,76,79,106,157,161,166,176,182,209,213,239,279,297],"failure":[20],"standard":[22],"statistical":[23],"approaches":[24],"capture":[26],"heterogeneity":[27],"treatment":[29],"response.":[30],"OBJECTIVE:":[31],"To":[32],"assess":[33],"whether":[34],"growth":[35],"mixture":[36],"modeling":[37],"can":[38],"provide":[39],"insights":[40],"into":[41],"antidepressant":[42,229,291,309],"responses":[45],"patients":[50,142,186,244,265,273],"with":[51,143,204,246],"major":[52,144],"depression.":[53,145],"DESIGN:":[54],"We":[55,74],"reanalyzed":[56],"duloxetine":[60,96,131],"identify":[62],"distinct":[63],"trajectories":[64,77,118,171],"Hamilton":[66],"Scale":[67],"for":[68,299],"Depression":[69],"(HAM-D)":[70],"scores":[71,222,235],"during":[72,289],"treatment.":[73,292,310],"analyzed":[75],"entire":[80,162],"sample":[81,163],"then":[83],"separately":[84],"all":[86,91],"active":[87],"arms":[88],"arms.":[93],"Effects":[94],"hydrochloride,":[97],"selective":[98],"serotonin":[99],"reuptake":[100],"inhibitor":[101],"(SSRI),":[102],"covariates":[104],"on":[105,156],"probability":[107],"following":[109,212],"a":[110,190,250],"particular":[111],"trajectory":[112,252],"were":[113,119,187],"assessed.":[114],"Outcomes":[115],"different":[117],"compared":[120,203],"using":[121],"mixed-effects":[122],"models.":[123],"SETTING:":[124],"Seven":[125],"randomized":[126],"double-blind":[127],"vs":[132],"comparator":[135,149],"SSRI.":[136,150],"Patients":[137],"A":[138],"total":[139],"2515":[141],"INTERVENTIONS:":[146],"Duloxetine":[147,194],"Main":[151],"Outcome":[152],"Measure":[153],"Total":[154],"score":[155],"HAM-D.":[158],"RESULTS:":[159],"In":[160],"antidepressant-treated":[167],"subsample,":[168],"we":[169],"identified":[170],"responders":[173,217],"(76.3%":[174],"sample)":[177],"nonresponders":[179,230],"(23.7%":[180],"sample).":[183],"However,":[184,263],"placebo-treated":[185,226,240,261],"characterized":[188],"by":[189],"single":[191],"trajectory.":[193,215],"SSRI":[196],"did":[197,269],"not":[198],"differ":[199],"efficacy,":[201],"they":[206],"significantly":[207,219,232],"decreased":[208],"odds":[210],"nonresponder":[214],"Antidepressant":[216],"had":[218,231],"better":[220],"HAM-D":[221,234],"over":[223,236,253],"time":[224,237,254],"than":[225,238,272],"patients,":[227],"but":[228],"worse":[233],"patients.":[241,262],"CONCLUSIONS:":[242],"Most":[243],"treated":[245],"serotonergic":[247,290],"antidepressants":[248],"showed":[249],"that":[255,259],"is":[256],"superior":[257],"some":[264],"receiving":[266,274],"these":[267],"medications":[268],"more":[270],"poorly":[271],"placebo.":[275],"These":[276],"data":[277],"highlight":[278],"importance":[280],"ongoing":[282],"monitoring":[283],"medication":[285],"risks":[286],"benefits":[288],"They":[293],"should":[294],"further":[295],"stimulate":[296],"search":[298],"biomarkers":[300],"or":[301],"other":[302],"predictors":[303],"responder":[305],"status":[306],"guiding":[308]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2162946017","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":13},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":18},{"year":2014,"cited_by_count":13},{"year":2013,"cited_by_count":12},{"year":2012,"cited_by_count":9}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2016-06-24T00:00:00"}
